Univec announces completion of R&D for Nicotine Replacement Patch
July 12 2012 - 7:07PM
Business Wire
Univec, Inc. (OTC: UNVC) a specialty pharmaceutical
company, announces it has completed the R&D for its Nicotine
Replacement Patch. Univec anticipates product production by the end
of next quarter. Univec's Transdermal Delivery system enhances
bioavailability, minimizes pharmaco-kinetic peaks, improves
tolerability and dosing, increases patient compliance, and
continuous delivery.
David L. Dalton, President and CEO of Univec stated, “We are
delighted to continue making progress in our new business model.
Over the last decade deaths due to smoking have increased
drastically. Over 45 million people smoke worldwide, 70% of the
people would like to quit. 440,000 deaths each year are caused by
smoking. City, States, Federal agencies recognize the need to stop
this and are providing financial assistance and Quitline programs
and products. We feel that our products will be one of the
solutions.”
About Univec
Univec, Inc., a minority business enterprise (MBE), is a
Specialty Pharmaceutical Company that manufactures and distributes
high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are
high cost products that are not usually dispensed in retail
pharmacies but require special handling and a complex
pharmaceutical regime. The company is focused on diseases such as
Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple
Sclerosis, Hemophilia and Smoking and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.), a
subsidiary of Univec, promotes and pays for pharmaceutical products
though its network of pharmacies. PPSI eliminates the need for the
pharmaceutical companies to distribute actual drug samples to
physicians reducing potential liability for the physician while
maintaining clinical oversight and drug interaction checks for the
patient. The company through its “StarterScript” allows in lieu of
a physician sample, a voucher or a co-payment card to be provided
to the patient for a trial supply of medication redeemed at any of
the nearly 55,000 retail pharmacies utilizing the PPSI real-time
processing system.
Forward Looking Statements
This document may contain forward-looking statements based on
current expectations that could be affected by the risks and
uncertainties involved in Univec’s business. These risks and
uncertainties include, but are not limited to, the risks described
from time to time in Univec’s reports to the General Public and
reporting agencies. Subsequent written or oral statements
attributable to Univec or persons acting on its behalf are
expressly qualified in their entirety by the cautionary statements
in this document and those in Univec’s reports filed.
Univec (PK) (USOTC:UNVC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Univec (PK) (USOTC:UNVC)
Historical Stock Chart
From Jan 2024 to Jan 2025
